Osprey to market efficiency of DyeVert

Osprey Medical has received FDA clearance for expanded marketing claims of dye savings, image quality and reflux reduction for the DyeVert System.

1 min read

Published 8 February 2016 11:35am

Updated 8 February 2016 7:06pm

Source: AAP

Share this with family and friends

The new expanded claims enable physicians to comply with cardiology and radiology society guidelines that urge physicians to use dye sparing approaches in patients at risk of contrast induced acute kidney injury.

Clinical use of the DyeVert System in over 100 patients from three different hospitals have shown an average of more than 45% dye savings without compromised image quality.

Sign up now for daily news from Australia and around the world. You can also subscribe to Insight's weekly newsletter for in-depth features and first-person stories.